Sling Therapeutics Presents Data from Phase 2b/3 LIDS Clinical Trial Demonstrating Durability of Linsitinib in Thyroid Eye Disease at ASOPRS 57th Annual Fall Scientific Symposium

Linsitinib achieved a statistically significant proptosis responder rate of 52% vs. 19% for placebo at Week 24 (p=0.010)

82% of Week 24 proptosis responders maintained their response through Week 72 (48 weeks after treatment completion), representing a highly favorable durability profile

Low incidence of IGF-1R–associated adverse events of special interest; no treatment-related hearing impairment reported

Confirmatory Phase 3 ORBIT pivotal trial currently enrolling moderate to severe active TED patients

ANN ARBOR, Mich., October 09, 2026--Sling Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the first and only late-stage oral small-molecule therapy for thyroid eye disease (TED), today announced the presentation of efficacy, safety and new durability results from its Phase 2b/3 LIDS trial of linsitinib in adults with moderate to severe active TED. The data were highlighted in an oral presentation and in a poster session at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) 57th Annual Fall Scientific Symposium.

Linsitinib is the first and only oral IGF-1R inhibitor in Phase 3 development and only small molecule therapy to significantly reduce proptosis in TED, with more convenient oral dosing compared to currently available IV and injectable IGF-1R inhibitors.

"Full LIDS results reinforce that linsitinib can deliver clinically meaningful proptosis reductions with a differentiated safety, delivery and durability profile," said Ryan Zeidan, Ph.D., President and Chief Executive Officer of Sling Therapeutics. "Importantly, the data demonstrate that for the majority of proptosis responders in the trial, those improvements held for nearly a year after their last dose. This durability is particularly encouraging for patients, who are facing a disease that can remain active for years and often returns after treatment. With our confirmatory pivotal Phase 3 ORBIT trial now enrolling, we are focused on building the evidence to establish linsitinib as a convenient oral treatment that can deliver meaningful and durable benefit for people living with TED."

"For physicians, Clinical Activity Scores are an important measure in determining whether TED is active and at risk of flaring. Data from LIDS indicates treatment with linsitinib resulted in sustained suppression of disease activity after treatment ended, with further improvement over the follow-up period," said Raymond Douglas, M.D., Ph.D., board-certified aesthetic and reconstructive oculoplastic surgeon. "Furthermore, quality of life scores among linsitinib responders continued to rise after treatment ended, alongside sustained proptosis improvement and low disease activity. For patients living with a visible, often distressing disease, that continued improvement off therapy is an important benefit."